2023
Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma
Li B, Li Y, Zhou H, Xu Y, Cao Y, Cheng C, Peng J, Li H, Zhang L, Su K, Xu Z, Hu Y, Lu J, Lu Y, Qian L, Wang Y, Zhang Y, Liu Q, Xie Y, Guo S, Mehal W, Yu D. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology 2023, 79: 289-306. PMID: 37540187, PMCID: PMC10789383, DOI: 10.1097/hep.0000000000000553.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPatient-derived xenograftsTransarterial chemoembolizationF1 subtypeMolecular classificationAnti-programmed cell death-1 therapyNovel molecular classificationCancer patient therapyCheckpoint inhibitorsBevacizumab treatmentPD-L1Immunosuppressive microenvironmentRNA sequencingPatient cohortHepatocellular carcinomaImmunological characteristicsTherapeutic strategiesPotential respondersPatient therapyYM-155Prognosis predictionPrecision therapySingle-cell RNA sequencingMetabolic subtypesTumor microenvironment
2016
Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment
Yamaguchi S, Hirata K, Toyonaga T, Kobayashi K, Ishi Y, Motegi H, Kobayashi H, Shiga T, Tamaki N, Terasaka S, Houkin K. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. PLOS ONE 2016, 11: e0167917. PMID: 27936194, PMCID: PMC5148016, DOI: 10.1371/journal.pone.0167917.Peer-Reviewed Original ResearchConceptsFMISO accumulationOverall survivalFMISO PETBEV treatmentPartial responseRecurrent gliomaPre-treatment clinical factorsCox proportional hazards modelRecurrent glioma patientsSignificant prognostic factorsOverall survival differenceHumanized monoclonal antibodyProportional hazards modelLonger OSPET appearanceBevacizumab treatmentPrognostic factorsRANO criteriaSurvival benefitClinical factorsMRI findingsRetrospective studySurvival differencesChemotherapeutic optionsMRI appearance
2013
Bevacizumab for acute neurologic deterioration in patients with glioblastoma
Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrainBrain NeoplasmsGlioblastomaHumansInpatientsKarnofsky Performance StatusMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultConceptsNeurologic dysfunctionNeurologic deteriorationOutpatient treatmentGlioblastoma patientsAcute neurologic dysfunctionDose of bevacizumabAcute neurologic deteriorationSevere neurologic dysfunctionQuality of lifeBevacizumab treatmentHospitalized patientsRetrospective reviewSteroid dependenceDexamethasone administrationRehabilitation admissionTumor locationPeritumoral edemaBevacizumabPatientsAbstractTextDysfunctionTreatmentGlioblastomaHospitalizationEdemaSurvival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses.
Huse J, Beal K, Zhang J, Kastenhuber E, Kaley T, Abrey L, Gutin P, Brennan C, Omuro A. Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses. Journal Of Clinical Oncology 2013, 31: 2057-2057. DOI: 10.1200/jco.2013.31.15_suppl.2057.Peer-Reviewed Original ResearchMedian overall survivalOverall survivalBevacizumab treatmentSurvival benefitNanoString gene expression assaysProspective phase II trialPhase II trialNew treatment optionsParaffin-embedded tissue blocksGBM molecular subtypesMGMT promoter methylationEvaluable ptsPrimary endpointII trialUnselected patientsTreatment optionsMolecular subtypesTumor volumeStereotactic radiotherapyBevacizumabSurvival advantageTherapeutic implicationsMolecular subclassesGlioblastomaTumors
2009
Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis
Dial E, Duh M, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis. Journal Of Clinical Oncology 2009, 27: 5112-5112. DOI: 10.1200/jco.2009.27.15_suppl.5112.Peer-Reviewed Original ResearchRenal cell carcinomaAI therapyAngiogenesis inhibitorsUS commercial health insurance claims databaseIV therapyAI groupTreatment of renal cell carcinomaCost of bevacizumabIntravenous bevacizumab treatmentTreated with sunitinibRetrospective claims database analysisHealth insurance claims databaseClaims database analysisInsurance Claims DatabaseTotal medical costsBevacizumab groupBevacizumab patientsBevacizumab treatmentCell carcinomaBevacizumabTreatment initiationSunitinibSorafenibTreatment periodOral administration
2008
Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease
Sims T, Williams R, Ng C, Rosati S, Spence Y, Davidoff A. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 2008, 144: 269-275. PMID: 18656635, PMCID: PMC2525799, DOI: 10.1016/j.surg.2008.04.009.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAutocrine CommunicationBevacizumabCell Line, TumorCell ProliferationDisease ProgressionFibroblast Growth Factor 2HumansMiceMice, SCIDNeuroblastomaReceptors, Vascular Endothelial Growth FactorSignal TransductionTumor Cells, CulturedVascular Endothelial Growth Factor AConceptsVascular endothelial growth factorLuciferase-expressing tumor cellsAnti-VEGF monoclonal antibodyUpregulation of proangiogenic factorsMaximal antitumor efficacyVEGF signaling inhibitionActivity of bevacizumabDecreased tumor burdenFibroblast growth factor expressionEndothelial growth factorGrowth factor expressionIn vitro studiesCytoreductive therapyIntraperitoneal bevacizumabBevacizumab treatmentTumor burdenDisseminated diseaseDisseminated neuroblastomaMaintenance therapyMinimal diseaseCombination therapyNeuroblastoma cell linesIn vivo studiesProlonged survivalAntitumor efficacyMinimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies
Oh Y, Wallace S, Taylor S, Herbst R, Lippman S, Karp D, Stewart D. Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies. Journal Of Clinical Oncology 2008, 26: 14507-14507. DOI: 10.1200/jco.2008.26.15_suppl.14507.Peer-Reviewed Original Research
2006
Angiogenesis inhibition in the treatment of lung cancer.
Vokes E, Herbst R, Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clinical Advances In Hematology And Oncology 2006, 4: 1-10; quiz 11-2. PMID: 17143257.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCarcinoma, Non-Small-Cell LungClinical Trials, Phase III as TopicDisease-Free SurvivalErlotinib HydrochlorideHemorrhageHumansLung NeoplasmsNeovascularization, PathologicPaclitaxelProtein Kinase InhibitorsQuinazolinesRandomized Controlled Trials as TopicRisk FactorsSurvival RateVascular Endothelial Growth Factor AConceptsNon-small cell lung cancerVascular endothelial growth factorLung cancerAntiangiogenic therapyNon-squamous cell non-small cell lung cancerAnti-VEGF monoclonal antibody bevacizumabSmall molecule tyrosine kinase inhibitorsRandomized phase II studyRandomized phase III trialEpidermal growth factor receptor inhibitor erlotinibPhase II studyAddition of bevacizumabPhase III trialsSignificant survival benefitCell lung cancerSignificant clinical benefitMonoclonal antibody bevacizumabComprehensive treatment approachTyrosine kinase inhibitorsEndothelial growth factorImportant therapeutic targetOngoing studiesNSCLC settingBevacizumab treatmentII study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply